JaLCDOI 10.18926/AMO/48567
フルテキストURL 66_3_271.pdf
著者 Lee, Shin-Wha| Kim, Yong-Man| Kim, Moon-Bo| Kim, Dae-Yeon| Kim, Jong-Hyeok| Nam, Joo-Hyun| Kim, Young-Tak|
抄録 The choice of chemotherapeutic drugs to treat patients with epithelial ovarian cancer has not depended on individual patient characteristics. We have investigated the correlation between in vitro chemosensitivity, as determined by the histoculture drug response assay (HDRA), and clinical responses in epithelial ovarian cancer. Fresh tissue samples were obtained from 79 patients with epithelial ovarian cancer. The sensitivity of these samples to 11 chemotherapeutic agents was tested using the HDRA method according to established methods, and we analyzed the results retrospectively. HDRA showed that they were more chemosensitive to carboplatin, topotecan and belotecan, with inhibition rates of 49.2%, 44.7%, and 39.7%, respectively, than to cisplatin, the traditional drug of choice in epithelial ovarian cancer. Among the 37 patients with FIGO stage Ⅲ/Ⅳ serous adenocarcinoma who were receiving carboplatin combined with paclitaxel, those with carboplatin-sensitive samples on HDRA had a significantly longer median disease-free interval than patients with carboplatin- resistant samples (23.2 vs. 13.8 months, p<0.05), but median overall survival did not differ significantly (60.4 vs. 37.3 months, p=0.621). In conclusion, this study indicates that HDRA could provide useful information for designing individual treatment strategies in patients with epithelial ovarian cancer.
キーワード chemosensitivity carboplatin HDRA (histoculture drug response assay) epithelial ovarian cancer
Amo Type Original Article
発行日 2012-06
出版物タイトル Acta Medica Okayama
66巻
3号
出版者 Okayama University Medical School
開始ページ 271
終了ページ 277
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22729108
Web of Science KeyUT 000305669700011